Insight Lifetech, a high-tech company dedicated to providing innovative solutions for cardiovascular disease precision intervention, will continue to provide more innovative products and services and provide changes to precision diagnosis and treatment of cardiovascular diseases.
Insight Lifetech (Chinese: 北芯生命科技) completed the Series D+ equity round recently. The amount was undisclosed. The round was led by Sherpa Healthcare Partners (Chinese: 夏尔巴投资), with the participation from Taiping Medical and Health Fund (Chinese: 太平医疗健康基金), Triwise Capital (Chinese: 勤智资本), Zhouji Tongli (Chinese: 周济同历), National Innovation Center (Chinese: 国创中心) and the existing shareholder Sequoia Capital China (Chinese: 红杉中国). China Renaissance (Chinese: 华兴资本) served as the exclusive financial advisor for this round.
The funds will be used to accelerate the marketing and capacity expansion of the company's product lines, and to develop and consolidate the research and development of innovative product lines.
Founded in 2015, Insight Lifetech is a leading company in the interventional cardiovascular device market, and has developed the first and only domestic fractional flow reserve system approved by the NMPA in China. The company has about 20 products with global patents or products under development, and has completed the commercialization of a complex and precise PCI one-stop solution platform. Besides, its 1st Generation Intravascular Ultrasound (IVUS) system was the first domestic IVUS system to enter into clinical trials and complete patient enrollment in China.
The company's competitors include Endovastec (Chinese: 心脉医疗), Lepu Medical (Chinese: 乐普医疗) and MicroPort (Chinese: 微创医疗).